Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 2115 of 5804
-
Lung cancer patients gain early access to promising new drug
Disease control TEMPORARILY_NOT_AVAILABLEThis is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Telisotuzumab vedotin prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the po…
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New imaging tool helps doctors see brain tumors more clearly
Diagnosis AVAILABLEThe participants are being asked to get this PET scan because the participants have or may have cancer in the central nervous system (head, neck, or spine), and the investigator and the patient's physician thinks that this scan may provide useful information for the participant's…
Sponsor: St. Jude Children's Research Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
ALS patients get expanded access to experimental Sugar-Based drug
Disease control NO_LONGER_AVAILABLEThis expanded access protocol is to provide access to the investigational product, SLS-005, to participants with ALS who are not eligible to participate in clinical trials.
Sponsor: Seelos Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 12:42 UTC
-
Last-Resort access to dupilumab for patients with severe inflammation
Disease control APPROVED_FOR_MARKETINGProvide Compassionate Use of Dupilumab
Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Second chance: yescarta offered to lymphoma patients despite manufacturing hiccups
Disease control AVAILABLEThe goal of this study is to provide access to axicabtagene ciloleucel for patients diagnosed with a disease approved for treatment with axicabtagene ciloleucel, that is otherwise out of specification for commercial release.
Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for ROS1+ cancer patients: expanded access to zidesamtinib
Disease control AVAILABLEThe Expanded Access Program will provide an alternate mechanism for these patients, who lack satisfactory therapeutic alternatives and cannot participate in a zidesamtinib clinical trial, to access investigational zidesamtinib.
Sponsor: Nuvalent Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug brensocatib offered to bronchiectasis patients who completed key trial
Disease control APPROVED_FOR_MARKETINGThe purpose of this study is to allow early access to brensocatib for participants with non-cystic fibrosis bronchiectasis (NCFBE) who have successfully completed the INS1007301 ASPEN Clinical trial.
Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Experimental drug offered to patients with rare gut condition
Disease control APPROVED_FOR_MARKETINGProvide compassionate use of pozelimab
Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Compassionate use of ritlecitinib offers hope for severe hair loss patients
Disease control AVAILABLEProvide pre-approval single patient Expanded Access (compassionate use) of Ritlecitinib for patients.
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New hope for rare blood and kidney diseases: iptacopan access program opens
Disease control AVAILABLEThe purpose of this registration form is to list all Managed Access Programs (MAPs) related to LNP023, Iptacopan
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Hope for rare fat disorder: expanded access to metreleptin offered
Disease control AVAILABLEMetreleptin was approved in the United States as adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy in February 2014. The approval was based on results obtained in 2 open-label, …
Sponsor: University of Michigan • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Last-Resort cell therapy offered to sarcoma patients
Disease control AVAILABLEThe purpose of this expanded access protocol (EAP) is to provide controlled access to Afamitresgene autoleucel, suspension for intravenous infusion that does not meet the commercial release specification (NC afami-cel). This EAP will be conducted at authorized treatment centers w…
Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Poop pills fight superbug infections!
Disease control AVAILABLEThe Fecal Microbiota Transplantation (FMT) product PRIM-DJ2727 is prepared from human stool from a healthy, screened donor. Requestors will contact the study team about the product (PRIM-DJ2727) by email, visit, or phone call. A screening list for donors will be provided to make…
Sponsor: Herbert DuPont, MD • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for catheter patients: expanded access to Infection-Fighting drug DefenCath
Prevention NO_LONGER_AVAILABLEThe EAP for DefenCath is designed to provide access to a broader population of adult and pediatric patients using catheters for various serious medical conditions. A key aspect of this EAP is its focus on individuals who, due to their unique clinical circumstances, are either ine…
Sponsor: CorMedix • Aim: Prevention
Last updated Jul 03, 2026 00:00 UTC
-
Desperate patients get early access to promising new drug
Disease control AVAILABLEProvide pre-approval single patient expanded access of retatrutide for patients.
Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Experimental device aims to tame disease without drugs
Disease control WITHHELDSponsor: [Redacted] • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental device aims to tame disease without drugs
Disease control WITHHELDSponsor: [Redacted] • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Experimental device aims to tame disease
Disease control WITHHELDSponsor: [Redacted] • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Lifeline for kids with severe epilepsy: drug access extended
Disease control AVAILABLEThis is an extended access study for participants who have completed Rufinamide Study E2080-G000-303 to continue to have access to rufinamide until it becomes commercially available in Poland or until no participants remain in the EAP.
Sponsor: Eisai Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Experimental device aims to tame disease
Disease control WITHHELDSponsor: [Redacted] • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC